Kornimate/medical-research-clean huggingface dataset:
improving neuromuscular monitoring and reducing residual neuromuscular blockade via e-learning

Conditions: Neuromuscular Blockade

Summary: to assess the impact of an e-learning course in neuromuscular monitoring on the frequency of application of objective neuromuscular monitoring for assessment of depth of neuromuscular blockade in general anaesthesia and secondarily on the incidence of residual neuromuscular blockade after anesthesia. we will collect data prospectively from 6 danish anaesthesia departments from the time of intervention, using data from the anaesthesia information management system (aims). baseline data is obtained from another study based on the same data extraction procedure (nct02914119).


Eligibility criteria:
inclusion departments we will include the 6 largest anaesthesia departments in the zealand region of denmark. anaesthetists we will include the following anaesthesia personnel as anaesthetists: nurse anaesthetists in training, nurse anaesthetists, first year residents in anaesthesiology, residents in the last 4 years of training in anaesthesiology, and specialist consultants in anaesthesia. patients we will include and collect data from all patients undergoing general anaesthesia with neuromuscular blockade in each data collection period. patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses with a case for every general anaesthetic received. exclusion criteria we will exclude personnel without clinical functions, i.e. administrative personnel.

Keywords: residual nerve blockade neuromuscular monitoring residual curarization neuromuscular blocking agents e-learning web based learning
ph iii study of lenalidomide and dexamethasone with or without elotuzumab to treat previously untreated multiple myeloma (elo 1 substudy)

Conditions: Newly Diagnosed, Previously Untreated Multiple Myeloma

Summary: the purpose of the study is to look at subjects who receive lenalidomide, dexamethasone, and elotuzumab and determine if they will have lower surface cs1 expression on malignant plasma cells at the time of progression than those who receive lenalidomide and dexamethasone without elotuzumab


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com. inclusion criteria: subjects who are newly diagnosed with symptomatic mm and who: * have not received any prior systemic anti-myeloma therapy * have measurable disease * and are not candidates for high-dose therapy plus stem-cell transplantation (sct) because of age (≥65 years) or coexisting conditions. refusal to undergo high dose therapy with sct is not sufficient for entry onto ca204-006 for a subject \<65 years old. there must be a comorbidity that prevents sct for a subject \<65 years old exclusion criteria: * subjects with non-secretory or oligo-secretory or free light-chain only myeloma * smoldering mm, defined as asymptomatic mm with absence of lytic bone lesions * monoclonal gammopathy of undetermined significance (mgus) * active plasma cell leukemia * known human immunodeficiency virus (hiv) infection or active hepatitis a, b, or c
women's knowledge about endometriosis

Conditions: Endometriosis

Summary: in the world, 10% of women of childbearing age have endometriosis with diagnostic mostly between 25 and 30 years old. endometriosis is the leading cause of infertility in our country. a diagnosis delay of approximately 6.7 years is observed for endometriosis.

the aim of the study will be to describe knowledge of women about endometriosis.

Eligibility criteria:
inclusion criteria: * women older than 18 * women of childbearing age * with or without gynecological history * agreed to participate in the study exclusion criteria: none

Keywords: women knowledge endometriosis
comparison of outcomes between hemodialysis and peritoneal dialysis patients in a multi-ethnic asian population

Conditions: Stage 5 Chronic Kidney Disease; Hemodialysis; Peritoneal Dialysis

Summary: end-stage renal disease (esrd) presents a heavy burden on a patient's psychological and social life, as well as overall quality of life (qol). health-related quality of life (hrqol) in dialysis patients measures the physical, social or emotional well-being that is affected by esrd and/or its treatment, and has been increasingly used as an outcome measure in interventional studies. additionally, associations between social support and qol have been observed, indicating that improved social support could improve hrqol, morbidity and mortality in esrd patients. however, it is not clear if hemodialysis (hd) and peritoneal dialysis (pd) have different impacts on hrqol. furthermore, comparisons of hrqol and social support between hd and pd patients in the multiethnic society of singapore have not been evaluated. as such, the investigators propose to conduct this cross-sectional study in the investigators local multiethnic esrd patient population to evaluate and compare patient-reported outcomes (hrqol and social support), economic and clinical laboratory outcomes in hd and pd patients. all chronic hd and pd patients seen in nuh outpatient renal or pd clinic will be included in this cross-sectional, observational study. information on patient demographics, medical/medication histories, dialysis vintage, clinical laboratory data and associated medical costs will be obtained from clinic notes, electronic medical records and hospital databases. patient-reported outcomes will be determined from scores of the kidney disease quality of life-short form, euroqol 5 dimensions, family functioning measure, oslo-3 social support scale, multidimensional scale of perceived social support, kessler psychological distress scale and health services utilization questionnaires (for indirect costs), and compared between hd and pd patients. results from this study will provide important hrqol information to assist renal physicians and patients to make treatment decisions. furthermore, intervention programs could be developed to improve social support based on patients' needs. these could in turn improve patients' hrqol, morbidity and mortality outcomes with minimal risks involved.


Eligibility criteria:
inclusion criteria: * all chronic hd and pd patients who are on regular follow-up with nephrologists in the nuh outpatient renal or pd clinic, and who meet the following criteria will be included in the study: male or female 21 years of age or older, with stage 5 ckd (egfr \<15 ml/min/1.73m2) and have been receiving hd or pd for at least 3 months. exclusion criteria: * transient dialysis patients, those have poor cognitive function or are not able to complete the questionnaires or give informed consent.
use of sglt2i in nohcm with hfpef

Conditions: Hypertrophic Cardiomyopathy; Heart Failure With Preserved Ejection Fraction

Summary: this study aims to evaluate the impact of sodium-dependent glucose transporters 2 inhibitor empagliflozin on the exercise capacity,symptoms of heart failure, cardiac function, myocardial remodeling and quality of life of nonobstructive hcm patients with hfpef.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of nonobstructive hypertrophic cardiomyopathy; * at least 18 years old; * lvef≥50% * elevated nt-probnp \>300 pg/ml for patients without atrial fibrillation (af), or \>900 pg/ml for patients with af at visit 1; * nyha ii-iv * capable of performing cardiopulmonary exercise test with an rer≥1.0 * signed and dated written informed consent and willing to return for clinical follow-up. exclusion criteria: * under-went septal reduction therapy within 3 months before screening; * acute decompensation heart failure within 3 months before screening; * symptomatic low bp or sbp\<100mmhg; * egfr\<30ml/min/1.73m2 * lvotg ≥30mmhg at rest or under provocation; * renal insufficiency with egfr\<50ml/min/1.73m2 * icd implantation or crt planned within 3 months; * women who are pregnant, or who plan to become pregnant while in the trial; * currently enrolled in another investigational device or drug trial; * combining any other clinical condition with a life expectancy less than 1 year.
the impact of perioperative gabapentin on chronic groin pain after inguinal hernia repair

Conditions: Peripheral Nerve Disorder Associated With Repair of Hernia

Summary: a common source of morbidity after ihr is chronic groin pain(cgp), usually defined as pain lasting longer than 3 months. gabapentin is an anticonvulsant that is also of benefit in the treatment of neuropathic pain. we propose a randomized, double-blind, placebo controlled study of the effect of gabapentin on cgp after ihr. their pain will be assessed with a visual analogue scale. for those reporting pain, the need for pain medication, or other treatment, and the effect of pain on their quality of life will be recorded.

over 500,000 inguinal hernia repairs(ihr) are performed in the united states annually. this is also one of the most common operations performed on the primarily young, male active duty population. a common source of morbidity after ihr is chronic groin pain(cgp), usually defined as pain lasting longer than 3 months. the incidence of cgp varies widely in published reports, but in the majority it is 25 to 30%. a major etiology of cgp is thought to be injury to inguinal nerves during surgery. gabapentin is an anticonvulsant that is also of benefit in the treatment of neuropathic pain. numerous studies have shown that gabapentin can decrease perioperative pain in patients undergoing surgeries such as hysterectomy, cholecystectomy and spine surgery. doses and medication regimens varied in these studies, one study in patients undergoing ihr who received a single dose of gabapentin preoperatively, showed a decrease in postoperative pain and in reported pain scores in the first 6 months. we propose a randomized, double-blind, placebo controlled study of the effect of gabapentin on cgp after ihr. patients will be given placebo or gabapentin. those given gabapentin, will be given 300 mg orally three times daily for a total of six doses with the first dose given on the morning of surgery. patients will be evaluated preoperatively and at 1, 6, 12 and 24 months after surgery. their pain will be assessed with a visual analogue scale. for those reporting pain, the need for pain medication, or other treatment, and the effect of pain on their quality of life will be recorded.

Eligibility criteria:
inclusion criteria: * male patients 18 years of age or older undergoing initial inguinal (bilateral or unilateral) hernia repair by any method (i.e. laparoscopic or open surgery) exclusion criteria: * age less than 18 years of age, recurrent hernias, emergency operations, already taking gabapentin, allergy to gabapentin, pre-existing chronic pain or psychiatric disorder

Keywords: inguinal hernia repair, chronic pain
food intake and iga microbiota in anorexia nervosa

Conditions: Anorexia Nervosa; Healthy Volunteer

Summary: anorexia nervosa is characterized by intestinal dysbiosis, related to the feeding behavior impairment presented by these patients. pathophysiologic hypotheses are involving the trouble of the microbiota-gut-brain axis in the field of mental diseases.

anorexia nervosa is characterized by intestinal dysbiosis, related to the feeding behavior impairment presented by these patients. here we aim to characterize the iga-coated fraction of bacteria from the intestinal microbiota, linked to the regulation of the mucosal immune system and the epithelium physiology. abnormalities of this microbiota are reported in inflammatory bowel disease and are associated to immune trouble. as food intake plays a key role in shaping microbiota, we aim to correlate data from iga microbiota to food intake specificity, and to anorexia nervosa phenotypes.

Eligibility criteria:
inclusion criteria: * female subject, adult, affiliated to a social security system, under the care of the eating disorder department of university hospital of st etienne * presenting a diagnosis of pure restrictive anorexia nervosa. for acute subgroup : bmi between 11 and 17.5 kg/m2, patient with a first episode of restrictive anorexia nervosa or with hyperphagic episodes. for the chronic subgroup: bmi between 11 and 17.5 kg/m2, disease evolving for more than 5 years. for healthy volunteer: bmi between 20 and 24 kg/m², stable weight for the last 3 months, no eating disorder or history of eating disorder exclusion criteria: * patient does not understand french. * laxative treatment in progress or stopped for less than 15 days, * antibiotic treatment in the two months preceding inclusion, * pre-pro or symbiotic treatment in progress or in the month preceding inclusion, * patient with one of the following comorbid disorders: celiac disease, chronic inflammatory bowel disease, lactose intolerance, unstabilized hyperthyroidism, unstabilized diabetes, * subject under legal protective measures.

Keywords: anorexia nervosa microbiota gut-brain-axis immunology (iga)
bariatric surgery and pharmacokinetics of lamotrigine

Conditions: Obesity, Morbid

Summary: changes to gastric ph, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. these factors are potentially influenced by bariatric surgery. little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. in this study the pharmacokinetic effects of bariatric surgery on lamotrigine are investigated.


Eligibility criteria:
inclusion criteria: * preparing to undergo gastric bypass or sleeve gastrectomy in central norway * being a norwegian citizen exclusion criteria: * having previously undergone resections in the gi-tract

Keywords: bariatric surgery gastrointestinal tract biological availability pharmacokinetics lamotrigine
electric muscle stimulation for patients with chronic respiratory failure

Conditions: Chronic Respiratory Failure; Critical Illness Myopathy

Summary: background: after mechanical ventilation, 5-20% of patients with acute respiratory failure would depend on ventilator support more than 14 days because of critical-illness weakness and their underlying diseases such as heart failure and chronic obstructive pulmonary disease. hypothesis: electric muscle stimulation(ems) will improve their muscle strength and shorten their ventilator days. design: randomized controlled trial. adult patients with mechanical ventilation more than 14 days are eligible. ems would be applied in experimental group 32 minutes/day on their bilateral thigh.

randomized controlled trial involves the adult patients with invasive mechanical ventilation more than 14 days. the participants were not eligible for active rehabilitation because of drowisness or weakness(medical research council (mrc) scale for muscle strength≦ grade 3). ems would be applied in experimental group 32 minutes/day on their bilateral thigh(quadriceps muscle).

Eligibility criteria:
inclusion criteria: * adult patient required mechanical ventilation more than 14 days * no ability for active endurance exercise because of poor consciousness or limb weakness. exclusion criteria: * pregnant women * limb wound/infection interfered with electric pad application * recent acute myocardial infarction or life-threatening arrhythmia * uncontrolled epilepsy * dying patients without attempt of ventilator weaning * absence of respiratory drive

Keywords: electric muscle stimulation mechanical ventilation chronic respiratory failure
gemcitabine in treating patients with advanced colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of gemcitabine in treating patients who have advanced colorectal cancer.

objectives: * determine the response rate in patients with advanced colorectal cancer treated with gemcitabine. * determine the toxic effects of this drug in these patients. * determine the progression-free survival of patients treated with this drug. outline: this is a multicenter study. patients receive gemcitabine iv continuously over 24 hours on days 1, 8, and 15. treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. patients are followed every 6 months. projected accrual: a total of 12-41 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: histologically confirmed advanced colorectal cancer that has failed at least 1 prior course of fluoropyrimidine-based chemotherapy measurable and/or evaluable disease patient characteristics: age: * 18 and over performance status: * 0-2 life expectancy: * at least 3 months hematopoietic: * wbc at least 3,000/mm3 * platelet count at least 100,000/mm3 hepatic: * bilirubin no greater than 2.5 times upper limit of normal (uln) * alt and/or ast no greater than 3 times uln (no greater than 10 times uln if * secondary to hepatic involvement by tumor renal: * creatinine no greater than 2.0 mg/dl cardiovascular: * no history of cardiac arrhythmias requiring chronic treatment beyond an * acute event (e.g., arrhythmias during severe electrolyte abnormalities * allowed) * no active cardiac disease requiring treatment other than hypertension, * stable angina, or chronic valvular disease other: * no other malignancy within the past 5 years except curatively treated * (including surgically cured) cancer * no serious medical or psychiatric illness that would preclude study * no active uncontrolled bacterial, fungal, or viral infection * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception prior concurrent therapy: biologic therapy: * not specified chemotherapy: * see disease characteristics * no more than 3 prior chemotherapy regimens * must have 1 prior fluorouracil-based regimen and 1 other cytotoxic agent * (e.g., irinotecan) * more than 4 weeks since prior chemotherapy * prior gemcitabine allowed * no other concurrent antineoplastic therapy endocrine therapy: * not specified radiotherapy: * more than 4 weeks since prior radiotherapy surgery: * more than 4 weeks since prior surgery

Keywords: stage iii colon cancer stage iv colon cancer stage iii rectal cancer stage iv rectal cancer recurrent colon cancer recurrent rectal cancer
a study to evaluate the efficacy and safety of crezet tablet

Conditions: Dyslipidemias

Summary: this observation study is to evaluate blood lipid-lowering effects and liver/renal safety, changes in hba1c and fpg in patients with dyslipidemia who administered crezet tablets for 24 weeks.

a subject who is diagnosed with dyslipidemia and scheduled to administer crezet tablets, will be enrolled in this study based on the doctor's medical decision. the crezet tablet will be administered for 24 weeks, and the data including demographic information, body measurement, vital signs and etc will be collected during the study period. the data collection point is as follows. 1. visit 1 (baseline, day 0) 2. visit 2 (at 12 weeks) 3. visit 3 (at 24 weeks)

Eligibility criteria:
inclusion criteria: 1. an adult male and female over 19 years of age 2. a patient with dyslipidemia who is scheduled to administer crezet tablets according to the medical judgment of the investigator based on permission 3. a person who voluntarily participates in the observational study and agrees in writing to comply with the subject's precautions during the study period after hearing and understanding the detailed explanation of the characteristics of the observational study and the drug to be studied exclusion criteria: 1. a person who is prohibited from administering according to the permission of the crezet definition * patients who overreact to the principal or component of the crezet definition * patients with active liver disease or patients with persistent high symptoms of serum aminotransferase levels * a patient with a muscle disease * a patient administered in combination with a cyclosporine-med * patients with severe renal failure (creatinine clearance (clcr) \< 30 ml/min) * women and lactating women who may be pregnant or pregnant * patients with genetic problems such as galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption 2. a person who has a history of taking crezet tablets within three months of the date of registration 3. a person who is deemed inappropriate to participate in this observational study based on the judgment of investigator.
study of tv-1106 in growth hormone-deficient adults

Conditions: Growth Hormone Deficiency

Summary: the primary objective of this study is to determine the efficacy of 6 months of treatment with tv-1106 compared with placebo on body fat composition.


Eligibility criteria:
inclusion: * males and females 18 years of age or over * diagnosis of adult growth hormone deficiency (ghd) for at least 6 months, or patients who have hypopituitarism from surgical resection * no history of exposure to any rhgh within the past 12 months prior to screening * stable, adequate doses of replacement hormones (adrenal, thyroid, estrogen, testosterone, vasopressin) for at least 3 months prior to screening * other criteria apply, please contact the investigator for more information exclusion: * patients with acute or chronic conditions or diseases that could confound results of the study or put the patient at undue risk as determined by the investigator * presence of contraindications to rhgh treatment * patients who have participated in another clinical trial with a new chemical/biological entity within 3 months of screening * patients with known active malignancy (excluding surgically removed basal cell carcinoma or carcinoma in situ of cervix) * patients with a previously treated pituitary tumor with evidence of tumor progression in the past year patients with a new diagnosis of pituitary adenoma or other intracranial tumor within 12 months of screening * presence of prader-willi syndrome, turner's syndrome, untreated adrenal insufficiency, active acromegaly in the past 5 years, or active cushing's syndrome in the past 1 year * patients with type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus as indicated by a glycated hemoglobin (hba1c) of ≥8% * patients using weight reducing agents or appetite suppressants * women who are pregnant or nursing, or planning pregnancy during the study period * other criteria apply, please contact the investigator for more information

Keywords: long acting growth hormone